Journal · Updated 2026-08-11
Luvo Health Review 2026: 52-Week Math, Four Named Pharmacies, and the Testing Question
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Luvo Health is the market's most unusual pricing document: it publishes plan-term totals in weeks — a 52-week compounded semaglutide plan at roughly twenty-three hundred twenty-seven dollars (one ninety-four per calendar month) and tirzepatide at thirty-four ninety-seven (two ninety-one) — against no-commitment four-week terms at two forty-nine and three thirty-nine, verified August 8, 2026. Distinctives, both directions: Luvo names four dispensing pharmacies (rare transparency), yet per the same audit states no 503A/503B status for any of them, makes no third-party testing or potency claim, and notes its own evaluation doesn't include lab testing; its all-fifty-states claim is qualified in its own terms. The math and the testing question are the whole review.
The week-math, translated
Two translation traps live in the structure. First, 52 weeks is thirteen four-week cycles, not twelve months — so Luvo's own per-cycle framing understates the calendar-month equivalent, which is why our records divide term totals by twelve calendar months (one ninety-four, two ninety-one) for comparability. Second, the commitment premium is steep: buying four weeks at a time costs two forty-nine/three thirty-nine — fifty-five and forty-eight dollars more per month than the year plan — and the year plan is a term commitment whose exit and refund mechanics belong in writing. Ranked, the annualized figures land upper-mid-market: one ninety-four semaglutide is double the ninety-nine committed floor; two ninety-one tirzepatide sits far above the one twenty-five-to-one thirty-nine tier and within sight of brand vials.
The transparency split, and verdict
Naming four pharmacies is genuinely better than the anonymous norm — it makes the fifteen-minute verification runnable times four — while the absence of stated 503A/B status, testing claims, or lab-work in the evaluation moves exactly the questions that matter onto you: each pharmacy's license class and standing on your state's lookup, and a certificate of analysis for your lot, requested in writing. The verdict follows the two halves: structurally more checkable than most, priced above nearly all — and at two ninety-one for committed tirzepatide, the honest cross-shop is the $299-to-$449 FDA-approved vial, which wins that comparison for most buyers on certainty per dollar.
Questions people ask
How much does Luvo Health cost per month?
Annualized from Luvo's published 52-week term totals: about $194/month for compounded semaglutide ($2,327 total) and $291 for tirzepatide ($3,497), verified August 8, 2026. No-commitment four-week terms run $249 and $339. Note 52 weeks is 13 four-week cycles — divide totals by 12 calendar months for fair comparison.
Does Luvo name its pharmacies?
Yes — four dispensing pharmacies, rare transparency — while stating no 503A/503B status for any, per an August 2026 audit, and making no third-party testing claim. Run each name through your state board lookup and request a certificate of analysis; the naming makes that possible, and the gaps make it necessary.
Is Luvo's tirzepatide worth $291 a month?
Against the market: it's more than double the $125–$139 committed floor and within $8–$158 of FDA-approved Zepbound vials ($299–$449), which offer sealed dosing and agency review. For most buyers at this price point, the brand comparison — not the compounded one — is the decision.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.